Ahead of a decision by Ohio officials on whether to add female orgasmic disorder (FOD) as a qualifying condition for the state’s medical marijuana program, a new study highlights the benefits that researchers say cannabis could offer people with the condition—including increased orgasm ease and satisfaction. The 10-page study, publishedContinue Reading
South Dakota activists have officially turned in what they believe will be more than enough valid signatures to put a marijuana legalization initiative on the state’s ballot for the third time this November. South Dakotans for Better Marijuana Laws (SDBML) delivered 29,030 signatures to the secretary of state’s office onContinue Reading
“I never expected that all of the cannabis that they would grow would stay on reservation lands, that they would only be sold on reservation lands.” By Peter Callaghan, MinnPost Ongoing negotiations between Gov. Tim Walz (D) and a group of Minnesota tribal nations could make the tribes major playersContinue Reading
With the federal government moving to reschedule marijuana, a Democratic congressman has issued a new memo on cannabis reform priorities to reflect renewed “optimism for the path ahead”—laying out suggestions to advance the issue both in Congress and administratively. Rep. Earl Blumenauer (D-OR), founding co-chair of the Congressional Cannabis Caucus,Continue Reading
Days after the Alaska House of Representatives approved a bill that would create a state task force to study how to license and regulate psychedelic-assisted therapy in the event of federal approval of substances such as MDMA and psilocybin, a Senate panel has already advanced the measure. The Senate JudiciaryContinue Reading
The head of the Internal Revenue Service (IRS) says marijuana industry banking access would make the agency’s job easier, and officials “shouldn’t just sit on our hands” as the federal government moves to reschedule cannabis. At a hearing before the House Appropriations Subcommittee on Financial Services and General Government onContinue Reading
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next month where an expert committee will examine the evidence behind the application. Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announcedContinue Reading
Medical marijuana businesses and regulators in Georgia are cheering last week’s announcement that the federal Drug Enforcement Administration (DEA) will move cannabis to Schedule III of the Controlled Substances Act (CSA). They say the change could expand patients’ access to marijuana through pharmacies, whereas it is currently available through justContinue Reading
Big Marijuana is the only winner with rescheduling Image Cannabis News May 7, 2024 The Rise of Big Marijuana: Who Really Wins with Federal Rescheduling? Last week the Biden administration recommended marijuana be rescheduled from a Schedule I to a Schedule III drug, and it sent the marijuana investment marketsContinue Reading
The head of the Drug Enforcement Administration (DEA) told lawmakers on Tuesday that it would be “inappropriate” for her to comment on the agency’s recent marijuana rescheduling determination because the rulemaking process is “ongoing.” About a week after the Justice Department confirmed DEA is seeking to move cannabis from ScheduleContinue Reading
